Metastasis-associated lung adenocarcinoma transcript 1 molecular mechanisms in gastric cancer progression

Table 1 MALAT1 overexpression and clinical characteristics in GC patients

Samples	Sample	Clinical implications	Ref.
61 GC/DM, 50 GC/NDM, 36 C	Plasma, tissue	Staging, Metastasis	Xia et al[38]
150 GC, 15 peritumoral paraffin-embedded	Tissue	OS, PFS	Li et al[49]
78 GC, 78 NTAT	Tissue	Staging, LNM	Li et al[52]
60 GC, 60 NTAT	Tissue	Staging, LNM, Tumor size	Zhang et al[53]
20 GC, 20 NTAT	Tissue	Metastasis	Chen et al[54]
70 GC, 70 C	Serum	Staging	Lu et al[39]
89 GC, 89 NTAT	Tissue	LNM, Tumor size	Yan et al[32]
64 GC, 64 NTAT, 64 C	Tissue, plasma	Metastasis	Zhu et al[33]
30 GC, 30 NTAT	Tissue	Vascular invasion, Lymphatic invasion	Esfandi et al[30]
37 GC, 37 NTAT	Tissue	Staging	Li et al[34]
30 GC, 30 NTAT	Tissue	OS	Dai et al[35]
24 GC, 24 NTAT, 24 GC/OXA	Tissue	Chemoresistance	Zhang et al[36]

C: control samples without cancer; GC: gastric cancer patients; GC/OXA: gastric cancer patients treated with oxaliplatin; GC/DM: gastric cancer patients with distant metastasis; CG/NDM: gastric cancer patients withoutmetastasis; LNM: lymph node metastasis; OS: overall survival; NTAT: nontumoral adjacent tissues of GC patients; PFS: progression-free survival.